Vardakas K Z, Matthaiou D K, Falagas M E
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Eur J Neurol. 2009 Jun;16(6):662-73. doi: 10.1111/j.1468-1331.2009.02615.x.
The objective of this review was to study the effectiveness of dexamethasone for the treatment of adult patients with bacterial meningitis. Data was extracted from randomized controlled trials (RCTs) comparing dexamethasone with placebo or no treatment and pooled using meta-analysis techniques. Treatment with dexamethasone was associated with a non-significant lower mortality than placebo or no treatment [odds ratio (OR) = 0.68, 95% confidence interval (CI) 0.45-1.04]. If a RCT conducted in Malawi was excluded from the analysis, dexamethasone was associated with lower mortality than placebo or no treatment (OR = 0.58, 95% CI 0.40-0.83). Dexamethasone was associated with lower mortality in patients with definite meningitis (OR = 0.55, 95% CI 0.31-0.96), short duration of symptoms (OR = 0.61, 95% CI 0.38-1.00), Streptococcus pneumoniae meningitis (OR = 0.26, 95% CI 0.08-0.78), patients in countries with high (OR = 0.45, 95% CI 0.23-0.87) and medium Human Development Index (OR = 0.65, 95% CI 0.42-1.00). No benefit was seen in patients with longer duration of symptoms (OR = 0.80, 95% CI 0.47-1.36) or no antibiotic use (OR = 0.68, 95% CI 0.36-1.28). Dexamethasone was associated with fewer episodes of hearing impairment in high quality RCTs (OR = 0.64, 95% CI 0.43-0.94). The currently available evidence suggests that dexamethasone should be administered to all adult patients with bacterial meningitis. Large studies are needed to clarify the role of the duration of symptoms, disease severity, and antibiotic administration before the initiation of treatment with dexamethasone on modifying the outcomes.
本综述的目的是研究地塞米松治疗成年细菌性脑膜炎患者的有效性。数据取自比较地塞米松与安慰剂或不治疗的随机对照试验(RCT),并采用荟萃分析技术进行汇总。与安慰剂或不治疗相比,地塞米松治疗的死亡率降低但无统计学意义[比值比(OR)=0.68,95%置信区间(CI)0.45-1.04]。如果将在马拉维进行的一项RCT排除在分析之外,地塞米松与低于安慰剂或不治疗的死亡率相关(OR = 0.58,95% CI 0.40-0.83)。地塞米松与确诊脑膜炎患者的死亡率降低相关(OR = 0.55,95% CI 0.31-0.96)、症状持续时间短(OR = 0.61,95% CI 0.38-1.00)、肺炎链球菌脑膜炎(OR = 0.26,95% CI 0.08-0.78)、人类发展指数高的国家的患者(OR = 0.45,95% CI 0.23-0.87)和中等人类发展指数的患者(OR = 0.65,95% CI 0.42-1.00)。症状持续时间较长的患者(OR = 0.80,95% CI 0.47-1.36)或未使用抗生素的患者(OR = 0.68,95% CI 0.36-1.28)未观察到益处。在高质量的RCT中,地塞米松与听力障碍发作次数较少相关(OR = 0.64,95% CI 0.43-0.94)。目前可得的证据表明,所有成年细菌性脑膜炎患者均应使用地塞米松。需要开展大型研究以阐明症状持续时间、疾病严重程度以及在开始使用地塞米松治疗前使用抗生素对改善预后的作用。